Essex Investment Management CO LLC Biomarin Pharmaceutical Inc Transaction History

Essex Investment Management CO LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 12, 2021	SELL	$74.73 - $90.69 $2.3 Million - $2.79 Million	-30,720 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$72.61 - $90.2 $1.09 Million - $1.36 Million	15,038 Added 95.89%	30,720 $2.69 Million
Q3 2020 Nov 12, 2020	SELL	$71.87 - $131.03 $2.12 Million - $3.87 Million	-29,530 Reduced 65.31%	15,682 $1.19 Million
Q2 2020 Aug 04, 2020	BUY	$79.55 - $124.22 $548,338 - $856,248	6,893 Added 17.99%	45,212 $5.58 Million
Q1 2020 May 04, 2020	BUY	$71.37 - $96.85 $35,114 - $47,650	492 Added 1.3%	38,319 $3.24 Million
Q4 2019 Feb 10, 2020	BUY	$64.27 - $86.37 $1.93 Million - $2.6 Million	30,074 Added 387.9%	37,827 $3.2 Million
Q3 2019 Oct 22, 2019	BUY	$67.4 - $85.11 $75,420 - $95,238	1,119 Added 16.87%	7,753 $523,000
Q2 2019 Aug 15, 2019	SELL	$80.35 - $93.9 $585,028 - $683,685	-7,281 Reduced 52.32%	6,634 $568,000
Q1 2019 May 15, 2019	SELL	$84.2 - $98.62 $5,136 - $6,015	-61 Reduced 0.44%	13,915 $1.24 Million
Q4 2018 Feb 06, 2019	SELL	$80.14 - $106.07 $550,000 - $727,958	-6,863 Reduced 32.93%	13,976 $1.19 Million
Q3 2018 Oct 16, 2018	BUY	$93.92 - $105.72 $789,491 - $888,682	8,406 Added 67.61%	20,839 $2.02 Million
Q2 2018 Jul 17, 2018	SELL	$76.01 - $99.03 $15,962 - $20,796	-210 Reduced 1.66%	12,433 $1.17 Million
Q1 2018 Apr 26, 2018	BUY	$77.67 - $92.63 $66,718 - $79,569	859 Added 7.29%	12,643 $1.03 Million
Q4 2017 Feb 05, 2018	BUY	$80.76 - $95.13 $215,063 - $253,331	2,663 Added 29.2%	11,784 $1.05 Million
Q3 2017 Oct 30, 2017	BUY	$80.6 - $94.95 $735,152 - $866,038	9,121	9,121 $849,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.5B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Essex Investment Management CO LLC, based on Form 13F filings with the SEC.

Stay updated on Essex Investment Management CO LLC with notifications on news.